Literature DB >> 24792411

Bone cancer pain: from mechanism to therapy.

Patrick W Mantyh1.   

Abstract

PURPOSE OF REVIEW: To review how common cancers such as breast, lung, and prostate cancers drive significant and frequently life-altering pain when the cells metastasize to bones. RECENT
FINDINGS: Similar to cancer, the factors that drive bone cancer pain evolve and change with disease progression. Bone cancer pain has both a nociceptive and neuropathic component. The nociceptive component is driven by the release of algogenic substances by tumor and their associated stromal cells, acidosis caused by bone-destroying osteoclasts, and mechanical destabilization and fracture of the bone. The neuropathic component is induced by tumor cell growth which injures and destroys the distal ends of nerve fibers that normally innervate the bone, as well as by inducing a highly pathological sprouting of both sensory and sympathetic nerve fibers.
SUMMARY: There is both a nociceptive and neuropathic component of bone cancer pain. In bone cancer pain, there is frequently a continual afferent drive of sensory nerve fibers that induces a peripheral and central sensitization. These mechanistic insights have begun to lead to advances in not only how we understand bone cancer pain but to the development of new therapies to treat bone cancer pain.

Entities:  

Mesh:

Year:  2014        PMID: 24792411      PMCID: PMC4068714          DOI: 10.1097/SPC.0000000000000048

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  54 in total

Review 1.  Molecular mechanisms of nociception.

Authors:  D Julius; A I Basbaum
Journal:  Nature       Date:  2001-09-13       Impact factor: 49.962

Review 2.  Neurotrophins and the immune system.

Authors:  José A Vega; Olivia García-Suárez; Jonas Hannestad; Marta Pérez-Pérez; Antonino Germanà
Journal:  J Anat       Date:  2003-07       Impact factor: 2.610

3.  Anti-NGF painkillers back on track?

Authors:  David Holmes
Journal:  Nat Rev Drug Discov       Date:  2012-04-30       Impact factor: 84.694

Review 4.  Generation of somatic sensory neuron diversity and implications on sensory coding.

Authors:  Yang Liu; Qiufu Ma
Journal:  Curr Opin Neurobiol       Date:  2010-10-01       Impact factor: 6.627

5.  Alterations in dorsal horn neurones in a rat model of cancer-induced bone pain.

Authors:  E C Urch; T Donovan-Rodriguez; H A Dickenson
Journal:  Pain       Date:  2003-12       Impact factor: 6.961

Review 6.  Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management.

Authors:  Laura McKelvey; George D Shorten; Gerard W O'Keeffe
Journal:  J Neurochem       Date:  2013-02       Impact factor: 5.372

Review 7.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

Review 8.  Adjuvant analgesics in cancer pain management.

Authors:  David Lussier; Angela G Huskey; Russell K Portenoy
Journal:  Oncologist       Date:  2004

Review 9.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

Review 10.  RANKL inhibition in the treatment of bone metastases.

Authors:  Allan Lipton; Susie Jun
Journal:  Curr Opin Support Palliat Care       Date:  2008-09       Impact factor: 2.302

View more
  60 in total

1.  Modulation of Nav1.8 by Lysophosphatidic Acid in the Induction of Bone Cancer Pain.

Authors:  Hai-Li Pan; Ben-Long Liu; Wei Lin; Yu-Qiu Zhang
Journal:  Neurosci Bull       Date:  2016-09-09       Impact factor: 5.203

Review 2.  Bone Pain and Muscle Weakness in Cancer Patients.

Authors:  Daniel P Milgrom; Neha L Lad; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Curr Osteoporos Rep       Date:  2017-04       Impact factor: 5.096

Review 3.  Opioids and Chronic Pain: Where Is the Balance?

Authors:  Mellar P Davis; Zankhana Mehta
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

4.  Which factors can aid clinicians to identify a risk of pain during the following month in patients with bone metastases? A longitudinal analyses.

Authors:  Ragnhild Habberstad; M J Hjermstad; C Brunelli; S Kaasa; M I Bennett; K Pardon; P Klepstad
Journal:  Support Care Cancer       Date:  2018-08-13       Impact factor: 3.603

Review 5.  Skeletal complications in cancer patients with bone metastases.

Authors:  Shunsuke Tsuzuki; Sun Hee Park; Matthew R Eber; Christopher M Peters; Yusuke Shiozawa
Journal:  Int J Urol       Date:  2016-08-03       Impact factor: 3.369

6.  Connexin 43 Mediates CXCL12 Production from Spinal Dorsal Horn to Maintain Bone Cancer Pain in Rats.

Authors:  Li-Hua Hang; Shu-Na Li; Hong Luo; Wei-Wei Shu; Zu-Min Mao; Yuan-Feng Chen; Lei-Lei Shi; Dong-Hua Shao
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

Review 7.  Cancer and Referred Facial Pain.

Authors:  Marcela Romero-Reyes; Antonia Teruel; Yi Ye
Journal:  Curr Pain Headache Rep       Date:  2015-08

8.  Mediation of Movement-Induced Breakthrough Cancer Pain by IB4-Binding Nociceptors in Rats.

Authors:  Joshua Havelin; Ian Imbert; Devki Sukhtankar; Bethany Remeniuk; Ian Pelletier; Jonathan Gentry; Alec Okun; Timothy Tiutan; Frank Porreca; Tamara E King
Journal:  J Neurosci       Date:  2017-04-24       Impact factor: 6.167

9.  Intrathecal administration of Resolvin D1 and E1 decreases hyperalgesia in mice with bone cancer pain: Involvement of endocannabinoid signaling.

Authors:  Iryna A Khasabova; Mikhail Y Golovko; Svetlana A Golovko; Donald A Simone; Sergey G Khasabov
Journal:  Prostaglandins Other Lipid Mediat       Date:  2020-07-31       Impact factor: 3.072

Review 10.  From Mechanism to Cure: Renewing the Goal to Eliminate the Disease of Pain.

Authors:  Theodore J Price; Michael S Gold
Journal:  Pain Med       Date:  2018-08-01       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.